MLL polyclonal antibody
* The price is valid only in USA. Please select country.
-
More Files
- More Functions
-
Specification
Product Description
Rabbit polyclonal antibody raised against synthetic peptide of MLL.
Immunogen
A synthetic peptide (conjugated with KLH) corresponding to amino acids 312-343 at C-terminus of human MLL.
Host
Rabbit
Reactivity
Human
Form
Liquid
Purification
Protein G purification
Recommend Usage
Immunohistochemistry (1:10-50)
The optimal working dilution should be determined by the end user.Storage Buffer
In PBS (0.09% sodium azide)
Storage Instruction
Store at 4°C. For long term storage store at -20°C.
Aliquot to avoid repeated freezing and thawing.Note
This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Applications
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)
Formalin-fixed and paraffin-embedded human cancer tissue reacted with the MLL polyclonal antibody (Cat # PAB2355) , which was peroxidase-conjugated to the secondary antibody, followed by AEC staining. This data demonstrates the use of this antibody for immunohistochemistry ; clinical relevance has not been evaluated. BC = breast carcinoma. -
Gene Info — MLL
Entrez GeneID
4297Protein Accession#
Q03164;HRX_HUMANGene Name
MLL
Gene Alias
ALL-1, CXXC7, FLJ11783, HRX, HTRX1, KMT2A, MLL/GAS7, MLL1A, TET1-MLL, TRX1
Gene Description
myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, Drosophila)
Omim ID
159555Gene Ontology
HyperlinkGene Summary
The MLL gene encodes a DNA-binding protein that methylates histone H3 (see MIM 601128) lys4 (H3K4) and positively regulates expression of target genes, including multiple HOX genes (see MIM 142980). MLL is a frequent target for recurrent translocations in acute leukemias that may be characterized as acute myeloid leukemia (AML; MIM 601626), acute lymphoblastic leukemia (ALL), or mixed lineage (biphenotypic) leukemia (MLL). Leukemias with translocations involving MLL possess unique clinical and biologic characteristics and are often associated with poor prognosis. MLL rearrangements are found in more than 70% of infant leukemias, whether the immunophenotype is more consistent with ALL or AML6, but are less frequent in leukemias from older children. MLL translocations are also found in approximately 10% of AMLs in adults, as well as in therapy-related leukemias, most often characterized as AML, that develop in patients previously treated with topoisomerase II inhibitors for other malignancies. More than 50 different MLL fusion partners have been identified. Leukemogenic MLL translocations encode MLL fusion proteins that have lost H3K4 methyltransferase activity. A key feature of MLL fusion proteins is their ability to efficiently transform hematopoietic cells into leukemia stem cells (Krivtsov and Armstrong, 2007 [PubMed 17957188]).[supplied by OMIM
Other Designations
CDK6/MLL fusion protein|MLL-AF4 der(11) fusion protein|MLL/GAS7 fusion protein|MLL/GMPS fusion protein|trithorax-like protein|zinc finger protein HRX
-
Interactome
-
Disease
-
Publication Reference
-
Detection of leukemia-associated MLL-GAS7 translocation early during chemotherapy with DNA topoisomerase II inhibitors.
Megonigal MD, Cheung NK, Rappaport EF, Nowell PC, Wilson RB, Jones DH, Addya K, Leonard DG, Kushner BH, Williams TM, Lange BJ, Felix CA.
PNAS 2000 Mar; 97(6):2814.
-
Detection of leukemia-associated MLL-GAS7 translocation early during chemotherapy with DNA topoisomerase II inhibitors.
- +1-909-264-1399
+1-909-992-0619
Toll Free : +1-877-853-6098 - +1-909-992-3401
- sales@abnova.com